Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza

NICE technology appraisal guidance [TA158] Published date:

6 Recommendations for further research

6 Recommendations for further research

6.1 Research is required into methods of delivering zanamivir to the under-5 age group and to establish the effectiveness of such treatment.

6.2 Research is required to develop options for prophylaxis of influenza in infants (under 12 months of age).

  • NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to the methods of technology appraisal' (2008). More information on accreditation can be viewed at www.nice.org.uk/accreditation
Get involved